You are here

EU regulators charge Teva over pay-for-delay drug deal

Monday, July 17, 2017 - 18:10

TEVA.jpg
EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's blockbuster sleep disorder drug.

[BRUSSELS] EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's blockbuster sleep disorder drug.

Teva, the world's biggest generic drugmaker, reached the deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of Cephalon's patents on the drug. This involved cash payments from Cephalon, which Teva later acquired in 2011.

The European Commission said the deal may have pushed up prices of the drug, modafinil.

"The patent settlement agreement between Cephalon and Teva may have caused substantial harm to EU patients and health service budgets," the EU competition enforcer said in a statement.

REUTERS

sentifi.com

Market voices on:

Nespresso
Pair your daily business read with the perfect cup of espresso.

Subscribe to The Business Times today to receive your very own Nespresso Inissia coffee machine worth $188.

Find out more at btsub.sg/btdeal

Powered by GET.comGetCom